Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial

References

• WHO. WHO coronavirus (COVID-19) dashboard. [cited 2022 Oct 25]. Available from: https://covid19.who.int/?topicsurvey=v8kj13)&gclid=EAIaIQobCIhMxL2d_4Sv-AIVYRLnCh2ZXwaDEAAYASACEgI9y_D_BwE
   Google Scholar
• WHO. COVID-10 vaccine tracker. [cited 2022 Oct 19]. Available from: https://covid19.trackvaccines.org/agency/who/
   Google Scholar
• Ong SWX, Chia T, Young BE. SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond. Expert Rev Respir Med. 2022;16(5):499–502.
   PubMed Web of Science ®Google Scholar
• Dolgin E. COVID vaccine immunity is waning – how much does that matter? Nature. 2021;597(7878):606–607.
   PubMed Web of Science ®Google Scholar
• WHO. Interim recommendations for heterologous COVID-19 vaccination schedules. [cited 2022 Oct 14]. Available from: https://www.who.int/news/item/16-12-2021-interim-recommendations-for-heterologous-covid-19-vaccine-schedules
   Google Scholar
• Wang K, Jia Z, Bao L, et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature. 2022;603(7903):919–925.
   PubMed Web of Science ®Google Scholar
• Yorsaeng R, Suntronwong N, Phowatthanasathian H, et al. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. Vaccine. 2022;40(3):524–530.
   PubMed Web of Science ®Google Scholar
• Cao Y, Hao X, Wang X, et al. Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine. Cell Res. 2022;32(1):107–109.
   PubMed Web of Science ®Google Scholar
• Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399(10324):521–529.
   PubMed Web of Science ®Google Scholar
• Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health. 2022;10(6):e798–e806.
   PubMed Web of Science ®Google Scholar
• Li JX, Wu SP, Guo XL, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022. DOI:10.1016/S2213-2600(22)00087-X
   Web of Science ®Google Scholar
• Nie J, Wu X, Ma J, et al. Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system. Sci Rep. 2017;7:42769.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Stephenson KE, Sadoff J, et al. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N Engl J Med. 2021;385(10):951–953.
   PubMed Web of Science ®Google Scholar
• Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021;384(23):2259–2261.
   PubMed Web of Science ®Google Scholar
• Gobeil P, Pillet S, Boulay I, et al. Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19. Nat Commun. 2022;13(1):6905.
   PubMed Web of Science ®Google Scholar
• Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602(7898):671–675.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211.
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43–50.
   PubMed Web of Science ®Google Scholar
• Ahmad L. Implication of SARS-CoV-2 immune escape spike variants on secondary and vaccine breakthrough infections. Front Immunol. 2021;12:742167.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101.
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;384(23):2254–2256.
   PubMed Web of Science ®Google Scholar
• Herrera-Comoglio R, Lane S. Vaccine-Induced immune thrombocytopenia and thrombosis after the Sputnik V vaccine. N Engl J Med. 2022;387(15):1431–1432.
   PubMed Web of Science ®Google Scholar
• Fraley E, LeMaster C, Khanal S, et al. The Impact of Prior Infection and Age on Antibody Persistence After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine. Clin Infect Dis. 2022;75(1):e902–e904.
   PubMedGoogle Scholar
• Desmecht S, Tashkeev A, El Moussaoui M, et al. Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and -experienced subjects: impact of booster dose and breakthrough infections. Front Immunol. 2022;13:863554.
   PubMed Web of Science ®Google Scholar
• Ferrari D, Di Resta C, Tomaiuolo R, et al. Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects. Vaccine. 2021;39(31):4256–4260.
   PubMed Web of Science ®Google Scholar
• Rubin R. Trying to block SARS-CoV-2 transmission with intranasal vaccines. JAMA. 2021;326(17):1661–1663.
   PubMed Web of Science ®Google Scholar